Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL... Love it.
.
Had me all exited for a moment... This:
https://nwbio.com/northwest-bio-proceeding-with-a-phase-iii-clinical-trial-of-dcvax-direct-for-all-solid-tumor-cancers/
Was actually this:
https://nwbio.com/northwest-bio-proceeding-with-a-phase-i/ii-clinical-trial-of-dcvax-direct-for-all-solid-tumor-cancers/
That little " / " makes a huge difference.
.
??? Why the difference in share quantity?
Low: MC - $2,355,528,793
SP - $2.19
1,075,583,923 shares
High: MC - $12,825,528,793
SP - $10.27
1,248,834,351 shares
Average: MC -$7,590,528,793
SP - $6.38
1,189,738,055 shares
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175048786
.
Quite frankly...
I believe Linda Powers has performed a miracle.
.
ROFLMFAO
.
......... A "short" version of the article... pun intended.
What's this document about?
The document primarily discusses the unique challenges faced by biotech companies, particularly those engaged in drug development, in dealing with short attacks and misinformation. ? It outlines the regulatory process for bringing a new drug to market, emphasizing the complexity and uncertainty involved in clinical trials. ? The impact of short attacks on biotechs, including the cascade effect on stock prices, difficulties in raising capital, and potential negative consequences on clinical trials and patient recruitment, is explored. ? The document also highlights the human costs of market manipulation, such as the impact on researchers and the potential delay or derailment of life-saving drugs due to short attacks. ? Additionally, it discusses the vulnerability of small biotechs to shorting compared to larger pharmaceutical companies, the importance of small biotechs in driving innovative research and development, and the potential consequences of short attacks on these companies, including hindering drug development efforts and impacting the availability of new drugs in the market. ? The document also covers the practice of short selling in financial markets, the impact of short selling on companies, investors, and market stability, the concept of "short & distort," and the role of activist short sellers in exposing corporate fraud. ? It further explores the recent GameStop short squeeze incident, regulatory measures in place to address market manipulation through short selling, challenges of distinguishing legitimate short reports from misinformation, and potential collusion between short sellers and media influencers to manipulate markets. ? Additionally, a detailed account of the history and challenges faced by Northwest Biotherapeutics, a biotech company specializing in developing personalized vaccines for solid tumor cancers, is provided, focusing on Glioblastoma Multiforme (GBM), clinical trial results, financial dealings, responses to negative press, stock market activities, legal issues, and the impact of external factors like online journalism and short selling on the company's operations and stock performance. ? The document also proposes a solution to address issues related to short attacks on small biotechs by suggesting a 15 percent surtax on profits from short-selling small biotechs, with the funds allocated to the National Institutes of Health for further research and development. ?
Who controls Northwest Bio through intertwined entities? The following seems to be dated information.
Linda Powers, the CEO and dominant shareholder of Northwest Biotherapeutics, controls the company through two intertwined entities she manages - Toucan Capital and Cognate Biosciences. ? Toucan Capital is an investment fund where Linda Powers was a former Managing Director, and Cognate Biosciences is the contract manufacturer of Northwest Bio's vaccine. ? Linda Powers' control over these entities allows her significant influence over Northwest Biotherapeutics.
What was the headline about Northwest Bio's vaccine trial results?
The headline about Northwest Bio's vaccine trial results was initially negative, claiming the trial was a failure, but later, positive results were published in a peer-reviewed journal validating the company's earlier announcement. ? The headline stated that a "global clinical trial" had shown that DCVax had "astonishing" results that enhanced survival for patients with deadly cancerous brain tumors. ? The headline also announced the positive Phase 1/2 trial results for DCVax®-L in Glioblastoma Brain Cancer. ?
What impact does misinformation have on biotech companies?
Misinformation has a significant impact on biotech companies, leading to consequences such as vulnerability to short attacks, difficulty in raising capital, impact on clinical trials, stock price manipulation, human costs, stock price volatility, investor confidence erosion, market manipulation, regulatory scrutiny, reputation damage, legal consequences, market perception distortion, loss of investor confidence, legal issues, reputational damage, impact on research and development, and public perception influence. ? This misinformation can result in financial instability, hindered progress in drug development, damaged reputations, and legal battles for biotech companies. ?
How did short sellers manipulate the market in NWBO stock?
Short sellers manipulated the market in NWBO stock through various tactics such as spreading false information, conducting short attacks, creating negative sentiment, triggering share price drops, issuing short reports, inducing panic selling, exploiting social media, making false statements, coordinating attacks, and engaging in fraudulent activities. ? These actions led to market volatility, manipulation, negative publicity, regulatory scrutiny, impacted reputation, investor confidence, and market perception. The manipulation involved illegal trading tactics, insider trading, obtaining confidential information, influencing scientific journals, pressuring editors, and breaching clinical trials. The manipulation resulted in significant profits for the trading firms involved and impaired NWBO's ability to raise funds and progress in drug development efforts.
I am looking forward to the documentary or the movie when all is done.
.
Wasn't there a combo trial for DC Vax L and Keytruda slated to end in August 2024???
.
Pharma awaits Fed relief with $1T in firepower to spend on biotech innovation: report
https://www.fiercebiotech.com/biotech/pharma-awaits-fed-relief-1t-firepower-spend-biotech-innovation-report
Sunday, 12/14/2014 6:53:48 PM
Northwest Biotherapeutics – Linda Powers’ Speech Transcript at the Oppenheimer 25th Annual Health Conference on 12-10-14.
Linda Powers: Yeah. We talk about this. Yeah, we talk about it all the time, because if this technology continues to perform in the way it has been so far and if it's going to applicable to most solid tumor cancers, you're talking about, not 10s of thousands of patients, you're talking of 100s and 100s of thousands of patients for whom it could be a fit. Umm, today the process, umm, the process is to, for the first product, DCVax-L, it's a manual process. For DCVax Direct, it's already partially-automated, the automation system. The answer can only be automation. Right? But, from a business standpoint, there's a point in which the lines cross. Right. We want to get to market and get the product to patients, as quickly as possible. Right, so we're going to do that the way that we're making it now. But, we're busily working, as is anyone who thinks about the future with a cell-therapy product, about end-to-end automation. And one of things about end-to-end automation is, is that it's both a capacity issue, a scale issue, because once you're fully automated in the end, you can virtually treat any number of patients. The other thing is, what people don't often realize is, it's going to further revolutionize your product economics. Why? Because when you make it by hand and there are steps that are open to the air, the whole facility has to be sterile, like a semi-conductor facility. It's massively capital intensive. And that's the biggest part of the finished cost of goods, is those indirect cost of that clean room infrastructure. Once it is automated end-to-end, that all goes out of the equation, because you just have rows and rows of these machines in a warehouse space. So you couple that with the batch manufacturing, and it's a step-change in terms of further enhancement of the economics. And so, everyone is busily working on automation. Umm, we think that's a couple-of-year process from where we are today. And we're working from some of the biggest and the best from all over the world.
I don't know why I can't see this previous same post... maybe it's because it was in response to "learning curve" who I have on ignore??? Anyway... here we go again!!!
.
Sunday, 12/14/2014 6:53:48 PM
Northwest Biotherapeutics – Linda Powers’ Speech Transcript at the Oppenheimer 25th Annual Health Conference on 12-10-14.
Linda Powers: Yeah. We talk about this. Yeah, we talk about it all the time, because if this technology continues to perform in the way it has been so far and if it's going to applicable to most solid tumor cancers, you're talking about, not 10s of thousands of patients, you're talking of 100s and 100s of thousands of patients for whom it could be a fit.[color=red][/color] Umm, today the process, umm, the process is to, for the first product, DCVax-L, it's a manual process. For DCVax Direct, it's already partially-automated, the automation system. The answer can only be automation. Right? But, from a business standpoint, there's a point in which the lines cross. Right. We want to get to market and get the product to patients, as quickly as possible. Right, so we're going to do that the way that we're making it now. But, we're busily working, as is anyone who thinks about the future with a cell-therapy product, about end-to-end automation. And one of things about end-to-end automation is, is that it's both a capacity issue, a scale issue, because once you're fully automated in the end, you can virtually treat any number of patients. The other thing is, what people don't often realize is, it's going to further revolutionize your product economics. Why? Because when you make it by hand and there are steps that are open to the air, the whole facility has to be sterile, like a semi-conductor facility. It's massively capital intensive. And that's the biggest part of the finished cost of goods, is those indirect cost of that clean room infrastructure. Once it is automated end-to-end, that all goes out of the equation, because you just have rows and rows of these machines in a warehouse space. So you couple that with the batch manufacturing, and it's a step-change in terms of further enhancement of the economics. And so, everyone is busily working on automation. Umm, we think that's a couple-of-year process from where we are today. And we're working from some of the biggest and the best from all over the world.
.
Off Topic, but of interest. Scroll down to view all topics listed.
https://www.fiercepharma.com/sponsored/positive-study-results-298-patients-obstructive-sleep-apnea-osa
The top 20 drugs by worldwide sales in 2023 - #1 is, yea... Keytruda - 25 Billion and growing.
The top 20 drugs by worldwide sales in 2023
The top 10 drugs losing US exclusivity in 2024
The top 10 biopharma M&A deals of 2023
Top 10 most anticipated drug launches of 2024
Do you suppose he is Ex Wannabe's boss... or is his boss Ex Wannabe???
.
So... the way a simpleton like me understands it...
DC-Vax L gives your overburdened immune system a new pair of 20/20 glasses, a well-fitting pair of sneakers, elbow and knee pads, the look and scent of those mother fuckin cancer cells... AND a whopping stick!!!
Have I expressed that right???
.
Gary...
Please tell me again how rich I'm going to be.
I hope this will make up for my $512K loss in an hour on Genvec.
.
Are we there yet???
A stock that should be trading in dollar increments is trading at 1,000ths of a penny. SICKENING.
.
So... My post got one (1) legitimate response and FOUR (4) fudster comments.
Yes, 7 years but there's a rumor that the 8th year is a charmer.
.
https://events.jspargo.com/asco24/public/eventmap.aspx?MapID=990&MapItBoothID=960026&MapItBooth=19131
WOW... NWBO booth = 80 x 80. It is among the largest booths there, right by the food court.
May 31st to June 4th.
I hope they have approval by then.
.
I believe I remember this... At a friend's funeral, the daughter's husband told me the company had a cure for HIV and it was going to $100... It was $4+ at the time... I looked into it and just wasn't impressed, but watched it run within a couple of months to mid $30s. It then paused there for quite a while and then took off gaining ~ $10 to $15 a day for several days. I remember it breaking $100. Don't remember where it finally turned at... but I do remember being sick about it.
'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study
https://www.fiercepharma.com/pharma/many-cancer-meds-approved-under-speedy-fda-pathway-didnt-prove-survival-benefits?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=9785H7211556F5N
Somewhat off topic but interesting.
.
Horseb4CarT
Buona Pasqua
.
Thanks, biosectinvestor.
.
Buona Fortuna Gary
EU Policy. Commission seeks faster approvals for biotech products.
https://www.euronews.com/health/2024/03/21/commission-seeks-faster-approvals-for-biotech-products
.
Thanxs Meirluc... So I guess that puts us into latter part of May.
It's hard for me to accept that 1.7 million pages can be digested in that time... but since it was requested it may be possible.
Been here 12 + years... but now I'm at the end of my rope.
.